Evaluation of Velusetrag Pharmacokinetics in Chronic Intestinal Pseudo-Obstruction: A Two-Part Study on Intravenous and Oral Administration in Healthy Subjects

The primary objective of this study is to evaluate the **pharmacokinetic** profile of velusetrag following single-dose administration of intravenous and oral capsule formulations in healthy male and female subjects. This is clinically relevant as it provides insights into the drug's absorption, distribution, metabolism, and excretion, which are crucial for determining the appropriate dosing regimen for patients with chronic intestinal pseudo-obstruction (CIPO). Understanding the pharmacokinetics of velusetrag can aid in optimizing therapeutic strategies for managing CIPO, a condition characterized by symptoms resembling a bowel obstruction without any physical blockage.

The clinical trial involves participants diagnosed with **chronic intestinal pseudo-obstruction (CIPO)**. The study population includes both male and female subjects, with an age range of 18 to 65 years. Participants are generally in stable health, excluding the condition under investigation. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. The selection process for the trial population and any key inclusion or exclusion criteria have not been disclosed by the sponsor.

The clinical trial is a **Phase 3** study designed to evaluate the pharmacokinetic profile of velusetrag following single-dose administration of intravenous and oral capsule formulations in healthy male and female subjects. The trial is structured as a two-part study, with a focus on determining the absolute bioavailability of the drug. The trial employs a **randomized**, **double-blind**, and **controlled** design to ensure the reliability and validity of the results. The estimated recruitment start date is September 16, 2024, with an anticipated end date of December 23, 2024, indicating an overall trial duration of approximately three months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation to ensure participants meet the necessary health standards for inclusion. Following successful screening, participants will be randomized into the study and will attend subsequent visits for drug administration and monitoring. These follow-up visits are critical for collecting pharmacokinetic data and ensuring participant safety. The end-of-study visit will conclude the trial, where final assessments will be conducted to gather any remaining data and evaluate the overall outcomes of the study.

The expected length of participant involvement is contingent upon the study's schedule, with each participant expected to remain in the trial for the duration of the study period unless specific conditions necessitate early termination. Such conditions may include adverse reactions to the study drug, non-compliance with study protocols, or withdrawal of consent by the participant. The study is focused on chronic intestinal pseudo-obstruction (CIPO), and the data collected will contribute to understanding the drug's efficacy and safety profile in this context.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on September 16, 2024, with an estimated completion date of December 23, 2024. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology to measure, collect, and analyze these efficacy parameters at predetermined timepoints throughout the study duration. The trial's design and execution will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy assessments. The study will utilize appropriate tools and instruments to facilitate accurate data collection and analysis, ensuring that the results are robust and clinically meaningful.